Pacira BioSciences
PCRX
200 hedge funds and large institutions have $3.48B invested in Pacira BioSciences in 2014 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 73 increasing their positions, 77 reducing their positions, and 36 closing their positions.
59% more call options, than puts
Call options by funds: $20.6M | Put options by funds: $12.9M
5% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 77
4% less funds holding
Funds holding: 208 → 200 (-8)
8% less capital invested
Capital invested by funds: $3.76B → $3.48B (-$285M)
11% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 36
56% less funds holding in top 10
Funds holding in top 10: 9 → 4 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$56.6M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$44.1M |
| 3 |
Bank of New York Mellon
New York
|
+$37.5M |
| 4 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$33.1M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$29.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$71.2M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$59.9M |
| 3 |
CCI
Columbus Circle Investors
|
-$40.6M |
| 4 |
Two Sigma Investments
New York
|
-$22.2M |
| 5 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$19.7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
226
Strategic Investment Management
Arlington,
Virginia
| – | -$236K | -2,436 | Closed |
|
|
PM
227
Parametrica Management
Wanchai,
Hong Kong
| – | -$235K | -2,425 | Closed |
|
|
CFB
228
Cullen/Frost Bankers
San Antonio,
Texas
| – | -$213K | -2,200 | Closed |
|
|
CEP
229
Chicago Equity Partners
Chicago,
Illinois
| – | -$208K | -2,150 | Closed |
|
230
BNP Paribas Financial Markets
Paris,
France
| – | -$203K | -2,094 | Closed |
|
|
WRM
231
Westport Resources Management
Westport,
Connecticut
| – | -$63K | -650 | Closed |
|
|
OA
232
OFI Advisors
Philadelphia,
Pennsylvania
| – | -$15K | -155 | Closed |
|
|
WAS
233
Winch Advisory Services
Appleton,
Wisconsin
| – | -$10K | -100 | Closed |
|
234
Envestnet Asset Management
Chicago,
Illinois
| – | -$3K | -26 | Closed |
|
|
PFO
235
Pathstone Family Office
Englewood,
New Jersey
| – | -$1K | -14 | Closed |
|
|
PTC
236
Private Trust Company
Cleveland,
Ohio
| – | -$1K | -9 | Closed |
|
PCRX Hedge Fund Activity: Q4 2014 in Review
200 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2014, worth a combined $3.48B — down 7.6% from $3.76B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of PCRX and 32 opened new positions — a net loss of 4 holders — while 77 trimmed existing stakes and 73 added.
The largest buyer was Jennison Associates, adding an estimated $56.6M. The largest seller was T. Rowe Price Associates, cutting an estimated $71.2M.
- 200 institutional investors held Pacira BioSciences (PCRX) as of Q4 2014, down from 208 in Q3 2014.
- Funds reported $3.48B of Pacira BioSciences stock for Q4 2014, down 7.6% quarter-over-quarter.
- 32 funds opened new Pacira BioSciences positions in Q4 2014 and 36 closed out, a net change of -4 holders.
- The largest Pacira BioSciences buyer in Q4 2014 was Jennison Associates, an estimated $56.6M added.
- The largest Pacira BioSciences seller in Q4 2014 was T. Rowe Price Associates, an estimated $71.2M sold.
Based on aggregated 13F filings for Q4 2014.